858.450.2800info@Sudoscan.com
SUDOSCAN® User LOGIN
The Role of SUDOSCAN® in the Management of Autoimmune Small Fiber Neur Skip to content
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store
  • Log in
  • YouTube
Cart


Subtotal
$0.00
Shipping, taxes, and discount codes calculated at checkout.
Your cart is currently empty.
SUDOSCAN Logo Powered by Withings SUDOSCAN Logo Powered by Withings Sudoscan Logo white SUDOSCAN Logo Powered by Withings
  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store
Log in Cart
Create Account
Schedule an online DEMO

Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Home / Research, Media & Events / The Role of SUDOSCAN® in the Management of Autoimmune Small Fiber Neuropathy
Neurological diseases · Scientific publications · Feb 18, 2023

The Role of SUDOSCAN® in the Management of Autoimmune Small Fiber Neuropathy

The Role of SUDOSCAN® in the Management of Autoimmune Small Fiber Neuropathy

SUDOSCAN® in autoimmune
small fiber neuropathy


Trevino, Jorge A. M.D., Novak, Peter MD. Ph.D.
Article title: TS-HDS and FGFR3 Antibodies in Small Fiber Neuropathy and Dysautonomia.
Muscle Nerve. 2021 Apr 1

JA Trevino and P Novak from Brigham and Women’s Hospital, Harvard Medical School, Boston conducted a study on small fiber neuropathy (SFN) in the idiopathic neuropathy population and investigated the autoimmune etiology of this complication. Autoimmune SFN is a neuropathy where autoimmunity is a causal factor. Immunological abnormalities may underlie up to 19% of patients with idiopathic SFN, according to one study.

Anti-TS-HDS or anti-FGFR3 antibodies have been discovered in patients with idiopathic sensory-predominant SFN, indicating that they could serve as useful markers of neural autoimmunity. Patients with evidence of autonomic dysfunction have TS-HDS/FGFR3 antibodies.

The goal of this retrospective study was to explain the SFN and autonomic profile of patients with anti-TS-HDS and anti-FGFR3.

Small fiber neuropathy was defined as a combination of clinical signs suggestive of small fiber dysfunction and at least one of the following structural or functional variables: abnormal epidermal nerve fiber density (ENFD); abnormal sweat gland nerve fiber density (SGNFD); abnormal sudomotor testing using SUDOSCAN’s measures (the following normative values were used for ESC*/kg: hands ≥1.03μS/kg, feet ≥1.14 μS/kg).

(*) ESC: electrochemical skin conductance

322 patients were included in the study, abnormal ENFD was detected in 71.4%, abnormal ESC/kg (SUDOSCAN) in 63.3%, and abnormal SGNFD in 48.8% of patients.

Frequency of positive or negative Anti-FGFR3 was significantly different among patients with mixed SFN (abnormal ENFD and SGNFD; and combined functional-morphological SFN (Abnormal ENFD, SGNFD, ESC measured with SUDOSCAN)) (see table below).

Only mixed SFN definition segregated seropositive from seronegative patients for anti-FGFR3 but not for anti-TSHDS.

SUDOSCAN measures combined to skin biopsy could be a helpful test to diagnose immune small fiber neuropathy.

Skin biopsy results and antibody presence

Skin biopsy results and antibody presence
Abbreviations: TS-HDS: Trisulfated heparin disaccharide antibody; FGFR3: Fibroblast growth factor
receptor 3 antibody; ENFD: Epidermal nerve fiber density; SGNFD: Sweat gland Nerve Fiber Density; ESC/kg: Electrochemical skin conductance adjusted for weight; +: abnormal results/positive antibody, -:
normal result/absent antibody.
Keywords: Small fiber neuropathy, autoimmune, TS-HDS, FGFR3, dysautonomia, ENFD, SGNFD, ESC, SUDOSCAN.
Abstract available here.
Share Share on Facebook Tweet Tweet on Twitter Pin it Pin on Pinterest

Back to Research, Media & Events
Invalid password
Enter
Sudoscan Logo

SUDOSCAN® is a privately-owned French medical device company.

Created in June 2005, SUDOSCAN is located in San Diego, CA, USA; the company's corporate headquarters are in Paris, France. We service all of the North and South America, The Middle East, Europe and Asia.

  • YouTube

Sudoscan

  • About SUDOSCAN®
  • Our Company
  • Research, Media & Events
  • Contact
  • Store

Shop SUDOSCAN

  • Login
  • Create an account

Resources

  • For Patients
  • For Physicians
  • SUDOSCAN® Articles
  • SUDOSCAN® Videos
  • SUDOSCAN® Image Gallery
  • Reimbursement Regulatory

CONTACT INFO:

US TERRITORIES:
SUDOSCAN Inc.
8525 Gibbs Dr. Suite 304
San Diego, CA 92123

Phone: +1 858 450 2800

INTERNATIONAL:
Impeto Medical
2 Rue Maurice Hartmann,
92130 Issy-les-Moulineaux,
France

Phone: +33 (0)7 87 20 32 03
Website: www.impeto-medical.com/

Promotional Communication. The medical devices SUDOSCAN® is cleared by the US Food and Drug Administration (FDA). The test allows screening and monitoring of peripheral autonomic neuropathies. It can be performed in diabetic patients or in patients suffering from neurological diseases involving small fibers damage. As with any diagnostic test, its results must be interpreted in a global context including the clinic and other examinations performed. Please read the user manual instructions carefully. Contact our office for more information. Last update: 05/10/2023

Language

  • English
  • Français

Currency

  • Canada (CAD $)
  • United States (USD $)
  • American Express
  • Apple Pay
  • Diners Club
  • Discover
  • Google Pay
  • Mastercard
  • Shop Pay
  • Visa
© 2023 SUDOSCAN USA | Autonomic & Sudomotor Testing Device Web Development
The Role of SUDOSCAN® in the Management of Autoimmune Small Fiber Neur